HOME >> BIOLOGY >> NEWS
Targeted Genetics presents clinical data on E1A cancer gene therapy

Phase II data and summary of Phase I studies presented at ASCO

New Orleans, LA-May 22, 2000-Targeted Genetics Corporation (Nasdaq: TGEN) yesterday presented data from its clinical studies of tgDCC-E1A, the Company's lead cancer therapy, at the 36th American Society of Clinical Oncology Annual Meeting in New Orleans, Louisiana. Dr. Thomas C. Reynolds, Vice President, Clinical Affairs at Targeted Genetics, presented data from clinical trials of tgDCC-E1A in patients with head and neck cancer or ovarian cancer at a poster discussion session on the topic of Biologic Therapy for cancer. Preclinical data from studies of a systemic delivery formulation of E1A also were presented in the same poster.

Data from a recently completed Phase II study of tgDCC-E1A in recurrent head and neck squamous cell carcinoma (HNSCC) were presented in an abstract titled "Activity of E1A in Human Clinical Trials." The Phase II study evaluated tgDCC-E1A as single-agent therapy in 24 patients with recurrent HNSCC. Patients received 30ug DNA/cm3 of tumor via intratumoral injection daily for three days and then weekly for seven weeks. The most common side effect was pain at the injection site, and no serious adverse events related to tgDCC-E1A were reported. Of 20 evaluable patients, 45% showed objective responses or stabilization of their disease as assessed by CT analysis. A 5% complete response rate also was observed by the same criteria. Tumor response was determined as a function of tumor growth measured by physical exam and by two-dimensional and three-dimensional CT analysis.

"These data suggest that tgDCC-E1A is safe and will be useful in the treatment of head and neck cancer," said Dr. Reynolds. "Although patients in this study had very advanced disease, we were able to generate a 45% response rate using tgDCC-E1A as a single agent. Preclinical studies show that E1A can sensitize tumors to radiation and chemotherapy and we believe that comb
'"/>

Contact: Page Sargisson
p.sargisson@noonanrusso.com
415-677-4455 x 229
Noonan/Russo Communications
21-May-2000


Page: 1 2 3

Related biology news :

1. Targeted therapy knocks out pediatric brain cancer in mice
2. Targeted therapy for lung cancer patients shows promise in extending lives
3. Targeted immunotherapy eradicates cancer in mice
4. Targeted radiation to liver tumors spares tissue, improves quality of life
5. Targeted Genetics presents data on arthritis gene therapy
6. Targeted genetics presents promising data from cystic fibrosis clinical trial
7. Targeted Genetics presents advances in systemic gene delivery technology
8. Targeted Genetics presents advances in synthetic gene delivery technologies
9. Ribozyme Pharmaceuticals, Inc. Demonstrates Potent Activity Of A Ribozyme Targeted Against The Hepatitis C Virus
10. Fred Hutchinson Cancer Research Center And Targeted Genetics Announces Issuance Of Braod Patent Covering Antigen-Specific T Cell Expansion
11. Marine Snail Toxin Targeted At African Toad Eggs Reveals Novel Impact On The Regulation Of Serotonin

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/11/2019)... ... 11, 2019 , ... A new report published by the Family Equality Council ... 77% of those aged 18 to 35 already have or are considering having children, ... and older.(1) Among all LGBTQ prospective parents, 41% are considering assisted reproductive technology (ART) ...
(Date:3/9/2019)... ... March 07, 2019 , ... StressMarq ... stress research tools today announced the publication of its recent PCT patent ... antibody, still at a pre-clinical stage of development, moves the company into the ...
(Date:3/5/2019)... (PRWEB) , ... March 05, 2019 , ... Join this ... how a metadata-driven approach will help data analysts and bioinformaticians focus on data analysis ... unify data that can come from different source systems. Some sources of data include:, ...
Breaking Biology News(10 mins):
(Date:3/19/2019)... Calif. (PRWEB) , ... March 19, 2019 , ... ... Konica Minolta, Inc. (Konica Minolta) today announced the formation of their inaugural Scientific ... the advancement of precision medicine that takes into account individual variability in genes, ...
(Date:3/19/2019)... Switzerland (PRWEB) , ... March ... ... at Tel HaShomer, the largest hospital in Israel and the Middle East ... manufacturing using the state-of-the-art Cocoon™ manufacturing platform. The partnership will enable Sheba ...
(Date:3/18/2019)... ... 18, 2019 , ... For more than 15 years, USDM Life Sciences ... science companies to easily comply with FDA 21 CFR Part 11 and EMA EudraLex ... service delivering end-to-end GxP compliance from vendor audit through ongoing validation maintenance, including every ...
(Date:3/14/2019)... ... March 14, 2019 , ... ... in Oklahoma City, OK. EyeCRO joins the Department of Veterans Affairs, the Oklahoma ... Center as the fifth institution in Oklahoma to receive this prestigious endorsement. ...
Breaking Biology Technology:
Cached News: